{
    "clinical_study": {
        "@rank": "104238", 
        "acronym": "TACE", 
        "arm_group": {
            "arm_group_label": "Raltitrexed", 
            "arm_group_type": "Experimental", 
            "description": "Ralititrexed, 4mg, every 4 weeks"
        }, 
        "brief_summary": {
            "textblock": "To evaluate the efficacy and safety of Raltitrexed for advanced colorectal cancer"
        }, 
        "brief_title": "Efficacy and Safety Study of Raltitrexed to Treat Advanced Colorectal Cancer", 
        "condition": "Colorectal Cancer Metastatic", 
        "condition_browse": {
            "mesh_term": [
                "Colorectal Neoplasms", 
                "Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "evaluate the efficacy and safety of Raltitrexed and oxaliplatin and lipiodol transcatheter\n      arthrial chemoembolization for in refractory colorectal carcinoma with liver metastases."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Histologically confirmed colorectal adenocarcinoma\n\n          2. Disease limited to the liver Unresectable disease by surgery or other local therapies\n\n          3. Age >18 years\n\n          4. ECOG performance status 0-2,Child pugh A or B\n\n          5. Expected survival \u2265 3 months\n\n          6. Adequate hematological, hepatic, and renal function\n\n        Exclusion Criteria:\n\n          1. Pregnant or lactating women\n\n          2. Patients with severe organ dysfunction or failure\n\n          3. With severe cardiovascular disease, or mental\n\n          4. Extraliver metastases"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "320", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01959061", 
            "org_study_id": "NJCTTQ-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Raltitrexed", 
                "description": "4mg, every 4 weeks,transhepatic arterial infusion", 
                "intervention_name": "Raltitrexed", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Raltitrexed", 
                "description": "100~150mg, every 4 weeks, transhepatic arterial infusion", 
                "intervention_name": "Oxaliplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Raltitrexed", 
                "description": "5-20ml, every 4 weeks, hepatic artery embolization", 
                "intervention_name": "lipiodol", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Oxaliplatin", 
                "Raltitrexed", 
                "Ethiodized Oil"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Advanced colorectal cancer of liver metastatic", 
        "lastchanged_date": "October 7, 2013", 
        "number_of_arms": "1", 
        "official_title": "Raltitrexed and Oxaliplatin and Lipiodol Transcatheter Arterial Chemoembolization for Advanced Colorectal Cancer", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "change of the lesion size in liver", 
                "measure": "lesion", 
                "safety_issue": "Yes", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "change of ECOG Performance Status", 
                "measure": "ECOG", 
                "safety_issue": "Yes", 
                "time_frame": "4 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01959061"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Nanjing Chia-tai Tianqing Pharmaceutical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Nanjing Chia-tai Tianqing Pharmaceutical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}